BioCardia Inc. (NASDAQ: BCDA)
$3.18
-0.3650 ( -10.30% ) 138.6K
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Market Data
Open
$3.18
Previous close
$3.54
Volume
138.6K
Market cap
$5.73M
Day range
$2.88 - $3.44
52 week range
$2.62 - $38.10
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 16 | Dec 06, 2023 |
8-k/a | 8K-related | 13 | Dec 05, 2023 |
8-k | 8K-related | 13 | Dec 05, 2023 |
8-k | 8K-related | 14 | Nov 29, 2023 |
8-k | 8K-related | 19 | Nov 16, 2023 |
8-k | 8K-related | 14 | Nov 14, 2023 |
8-k | 8K-related | 14 | Nov 08, 2023 |
10-q | Quarterly Reports | 60 | Nov 08, 2023 |
4 | Insider transactions | 1 | Oct 19, 2023 |
4 | Insider transactions | 1 | Oct 19, 2023 |